Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.

IF 7.9 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2025-07-10 DOI:10.3324/haematol.2025.287777

Tracy Murphy,Boyang Zhang,Tong Zhang,Ian King,Jose-Mario Capo-Chichi,Vikas Gupta,Dawn Maze,Caroline J McNamara,Mark D Minden,Aaron D Schimmer,Andre C Schuh,Hassan Sibai,Karen W L Yee,Andrea Arruda,Zhibin Lu,Dina Khalaf,Chantal Rockwell,Brian Leber,Mitchell Sabloff,Anne Tierens,Tracy L Stockley,Steven M Chan,Stanley W K Ng,Jean C Y Wang

{"title":"Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.","authors":"Tracy Murphy,Boyang Zhang,Tong Zhang,Ian King,Jose-Mario Capo-Chichi,Vikas Gupta,Dawn Maze,Caroline J McNamara,Mark D Minden,Aaron D Schimmer,Andre C Schuh,Hassan Sibai,Karen W L Yee,Andrea Arruda,Zhibin Lu,Dina Khalaf,Chantal Rockwell,Brian Leber,Mitchell Sabloff,Anne Tierens,Tracy L Stockley,Steven M Chan,Stanley W K Ng,Jean C Y Wang","doi":"10.3324/haematol.2025.287777","DOIUrl":null,"url":null,"abstract":"Acute myeloid leukemia (AML) patients exhibit diverse molecular and cytogenetic changes with heterogeneous outcomes. The functionally-derived LSC17 gene expression score has demonstrated strong prognostic significance in retrospective analyses of adult and pediatric AML cohorts, where above-median scores are associated with worse outcomes compared to below-median scores in intensively-treated patients. Here we used a laboratory-developed clinically-validated NanoStringbased LSC17 assay to test the prognostic value of the LSC17 score in a prospective multicentre study of 276 newly-diagnosed AML patients. Each patient's score was classified as high or low by comparison to a previously-established reference score. In the entire cohort, a high LSC17 score was associated with poor risk features, including advanced age and unfavorable genetic mutations. In the subset of 190 patients treated intensively, a high LSC17 score was associated with lower remission rates (63% vs 94% after induction, P.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"4 1","pages":""},"PeriodicalIF":7.9000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3324/haematol.2025.287777","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Acute myeloid leukemia (AML) patients exhibit diverse molecular and cytogenetic changes with heterogeneous outcomes. The functionally-derived LSC17 gene expression score has demonstrated strong prognostic significance in retrospective analyses of adult and pediatric AML cohorts, where above-median scores are associated with worse outcomes compared to below-median scores in intensively-treated patients. Here we used a laboratory-developed clinically-validated NanoStringbased LSC17 assay to test the prognostic value of the LSC17 score in a prospective multicentre study of 276 newly-diagnosed AML patients. Each patient's score was classified as high or low by comparison to a previously-established reference score. In the entire cohort, a high LSC17 score was associated with poor risk features, including advanced age and unfavorable genetic mutations. In the subset of 190 patients treated intensively, a high LSC17 score was associated with lower remission rates (63% vs 94% after induction, P.

查看原文本刊更多论文

LSC17评分用于新诊断急性髓性白血病患者风险预测的真实世界验证研究

急性髓性白血病（AML）患者表现出不同的分子和细胞遗传学变化和不同的结果。功能来源的LSC17基因表达评分在成人和儿童AML队列的回顾性分析中显示出很强的预后意义，在强化治疗的患者中，高于中位数的评分与低于中位数的评分相比，预后更差。在此，我们使用实验室开发的临床验证的基于nanostring的LSC17检测方法，在276例新诊断的AML患者的前瞻性多中心研究中测试LSC17评分的预后价值。通过与先前建立的参考评分进行比较，每个患者的评分被分为高或低。在整个队列中，高LSC17评分与较差的风险特征相关，包括高龄和不利的基因突变。在接受强化治疗的190例患者中，高LSC17评分与较低的缓解率相关(诱导后为63% vs 94%， P。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.